Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Constitutive KRAS signalling drives tumorigenesis across several cancer types. In non-small-cell lung cancer (NSCLC) activating mutations occur in ~30% of cases, and the glycine to cysteine substitution at codon 12 (G12C) is the most common alteration. Although mutations have been considered undruggable for over 40 years, the recent discovery of allelic-specific KRAS inhibitors has paved the way to personalized cancer medicine for patients with tumours harbouring these mutations. Here, we review the current treatment landscape for patients with advanced NSCLCs harbouring a G12C mutation, including PD-(L) 1-based therapies and direct KRAS inhibitors as well as sequential treatment options. We also explore the possible mechanisms of resistance to KRAS inhibition and strategies to overcome resistance in patients with G12C-mutant NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677952 | PMC |
| http://dx.doi.org/10.7573/dic.2022-7-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of Targetable Mutations in Ovarian Cancer.
JCO Precis Oncol
September 2025
Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA.
Purpose: mutations are classically seen in non-small cell lung cancers (NSCLCs), and EGFR-directed inhibitors have changed the therapeutic landscape in patients with -mutated NSCLC. The real-world prevalence of -mutated ovarian cancers has not been previously described. We aim to determine the prevalence of pathogenic or likely pathogenic mutations in ovarian cancer and describe a case of -mutated metastatic ovarian cancer with a durable response to osimertinib, an EGFR-directed targeted therapy.
View Article and Find Full Text PDFUltrasound-Enhanced Delivery of Salvianolic Acid F Targets CXCL5 to Suppress Lung Cancer Progression: Insights from PC9 and H1299 Models.
Cancer Biother Radiopharm
September 2025
School of Food Science, Nanjing Xiaozhuang University, Nanjing, China.
Lung cancer remains one of the leading causes of cancer-related mortality worldwide, highlighting the urgent need for more effective and targeted therapeutic strategies. Traditional Chinese Medicine (TCM), known for its favorable safety profile and broad pharmacological effects, offers promising candidates for cancer treatment. Salvianolic acid F (SAF), a key bioactive compound derived from , has demonstrated antitumor potential, but its role and underlying mechanisms in lung cancer remain inadequately characterized.
View Article and Find Full Text PDFConcomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung Cancer.
JAMA Netw Open
September 2025
Oncostat U1018, Institut National de la Santé et de la Recherche Médicale (INSERM), Ligue Contre le Cancer, Paris-Saclay University, Villejuif, France.
Importance: Antibiotics, steroids, and proton pump inhibitors (PPIs) are suspected to decrease the efficacy of immunotherapy.
Objective: To explore the association of comedications with overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC).
Design, Setting, And Participants: This nationwide retrospective cohort study used target trial emulations of patients newly diagnosed with NSCLC from January 2015 to December 2022, identified from the French national health care database.
Aucubin inhibits the activity of lung cancer stem-like cells by targeting degradation of β-catenin.
J Pharm Pharmacol
September 2025
Department of Clinical Pharmacy, Hebei Medical University Third Hospital. No. 139 Ziqiang Road, Qiaoxi District, Shijiazhuang 050051, China.
Objectives: To investigate the antitumor effects of aucubin (AC) in non-small cell lung cancer (NSCLC) and uncover its plausible mechanism against lung cancer stem-like cells (LCSCs).
Methods: In vitro experiments included MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a reagent commonly used for cell viability assay) and colony formation assays to assess anti-proliferative effects on A549 and NCI-H1975 lung cancer cell lines, wound healing and Transwell invasion assays to evaluate inhibition of cell migration and invasion, tumorsphere-formation experiments to detect changes in NSCLC cell stemness, as well as Western blot and quantitative reverse transcription polymerase chain reaction (qRT-PCR) analyses to measure the expression of LCSC markers (CD44, CD133, Oct4, and Nanog). In vivo experiments were conducted to observe the impact of AC on NSCLC metastasis and mouse survival rates.
Development and validation of a novel nomogram model for predicting postoperative survival of T4N0M0 NSCLC: a population-based survival analysis.
Int J Surg
September 2025
Department of Thoracic Surgery, Changchun Tumor Hospital.
Objective: The risk factors of postoperative survival in T4N0M0 NSCLC patients are not fully understood. This study aimed to develop and validate a nomogram model for predicting postoperative survival in patients with T4N0M0 non-small cell lung cancer (NSCLC).
Methods: Clinicopathological data of patients were collected from Surveillance, Epidemiology, and End Results (SEER) database.